We are delighted to announce that Amy Crouch has joined the firm as a partner as of 1 October 2025, further strengthening our patent litigation capabilities in the UK and Europe.
Amy is a life sciences expert and brings extensive experience of high-profile patent litigation involving some of the highest-revenue pharmaceuticals on the market. Her experience spans the full spectrum of life sciences patent disputes before the UK courts, ranging from small molecule and biologic disputes to the UK’s first gene therapy patent case to go to trial last year.
Amy also brings a wealth of experience coordinating multi-jurisdictional litigation across Europe and with the US, as well as aligning litigation strategy with opposition proceedings before the EPO. She also has experience of acting for clients on UPC litigation and of advising clients on the ever-increasing importance of UPC litigation strategy and its integration with UK and European national litigation strategy.
With this appointment, we are further expanding our litigation expertise and reinforcing our ability to guide clients through this new era of European patent litigation as the UPC redefines the landscape.
Amy’s arrival follows the recent hire of partner Camilla Balleny, an accomplished litigator with almost two decades of experience, who joined Mewburn Ellis in May of this year as our Head of Patent Litigation. Camilla has since been working to develop and expand our litigation practice and Amy’s hire is reflective of the firm’s commitment to growth in this area and its rapidly evolving UPC practice, led by Matthew Naylor.
In addition to this, we recently announced that Susannah Dragosavac, a digital health and med-tech litigation specialist, also joined us on the 1st October, enhancing the firm’s ability to support clients in these rapidly evolving sectors.
Commenting Amy’s appointment, Chairperson Richard Johnson said:
“We’re delighted to welcome Amy to the firm – her arrival reflects our ongoing commitment to our international litigation offering, which continues to be a growth area for the firm.
Amy’s expertise will be invaluable as we continue to support clients involved with high-stakes patent disputes in the UK courts, cross-border litigation, the UPC and the rapidly evolving life sciences landscape.”
Amy added:
“I’m thrilled to be joining Mewburn Ellis as such an exciting time in the firm’s growth. With the expansion of its litigation capabilities and its excellent reputation in the life sciences sector, Mewburn Ellis is ideally placed to support clients through the increasingly complex landscape of pan-European patent disputes. I look forward to working alongside my new colleagues to deliver the first-class strategic service that our clients need.”
-1.png)